Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Fibronectin containing extra domain A (
EDA
+
FN), a functional glycoprotein participating in several cellular processes, correlates with chronic liver disease. Herein, we aim to investigate the expression and secretion of
EDA
+
FN from hepatocytes in nonalcoholic
fatty liver
disease (NAFLD) and the underlying mechanisms. Circulating levels of
EDA
+
FN were determined by ELISA in clinical samples. Western blotting and flow cytometry were performed on L02 and HepG2 cell lines to analyze whether the levels of
EDA
+
FN were associated with endoplasmic reticulum (ER) stress-related cell death. Circulating levels of
EDA
+
FN in NAFLD patients were significantly higher than those in control subjects, and positively related with severity of ultrasonographic steatosis score. In cultured hepatocytes, palmitate up-regulated the expression of
EDA
+
FN in a dose-dependent manner. Conversely, when the cells were pretreated with 4-phenylbutyrate, a specific inhibitor of ER stress, up-regulation of
EDA
+
FN could be abrogated. Moreover, silencing CHOP by shRNA enhanced the release of
EDA
+
FN from hepatocytes following palmitate treatment, which was involved in ER stress-related cell damage. These findings suggest that the up-regulated level of
EDA
+
FN is associated with liver damage in NAFLD, and ER stress-mediated cell damage contributes to the release of
EDA
+
FN from hepatocytes.
...
PMID:ER stress-mediated cell damage contributes to the release of EDA
+
fibronectin from hepatocytes in nonalcoholic fatty liver disease. 2839 39
